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Abstract 26 
Several studies investigating the effect of caffeine on immune function following exercise 27 
have used one large bolus dose of caffeine.  However, this does not model typical caffeine 28 
consumption.  Therefore the purpose of this study was to investigate whether small repeated 29 
doses of caffeine ingested throughout the day would elicit a similar response as one large 30 
bolus dose ingested 1 h prior to exercise on antigen-stimulated NK cell CD69 expression 31 
following strenuous intermittent exercise.  In a randomized cross-over design, 15 healthy 32 
males completed six 15 min blocks of intermittent running consisting of maximal sprinting 33 
interspersed with less intense running and walking.  Participants had ingested either 0 (PLA), 34 
2 mg·kg-1 body mass (BM) caffeine on 3 separate occasions during the day (3xCAF) or 1 35 
dose of 6 (1xCAF) mg·kg-1 BM caffeine, 1 h before exercise.  At 1 h post-exercise the 36 
number of antigen-stimulated CD3-CD56+ cells expressing CD69 was lower on 1xCAF 37 
compared with PLA [P<0.05; PLA: 42.0 (34.0)x106 cells·L-1, 1xCAF: 26.2 (25.0)x106 38 
cells·L-1], with values on 1xCAF at this time-point remaining close to pre-supplement.  39 
1xCAF tended to attenuate the exercise-induced increase in geometric mean fluorescence 40 
intensity of CD69 expression on antigen-stimulated CD3-CD56+ cells 1 h post-exercise 41 
[P=0.055; PLA: 141 (28)%, 1xCAF: 119 (20)%].  These findings suggest that although one 42 
large bolus dose of caffeine attenuated the exercise-induced increase in antigen-stimulated 43 
NK cell CD69 expression 1 h following strenuous intermittent exercise, this attenuation at no 44 
point fell below pre-supplement values and as such caffeine does not appear to depress NK 45 
cell CD69 expression.   46 
 47 
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 56 
Introduction 57 
Caffeine is a common element in most people’s diets (Heatherley et al. 2006), yet it is not a 58 
typical nutrient nor is it essential for health (Graham 2001).  Caffeine is legally and socially 59 
acceptable and as such is the most widely consumed behaviour-influencing substance in the 60 
world (Graham 2001).  It is estimated that the mean daily intake of caffeine in the U.K is 61 
~241 ± 173 mg·day-1, which is the equivalent to around 2-4 cups of coffee (Heatherley et al. 62 
2006).  However, daily caffeine intake can vary widely depending upon country. For example 63 
the daily caffeine intake in Sweden, Norway and Netherlands is estimated to be 64 
approximately 400 mg·day-1 (Fredholm et al. 1999). 65 
 66 
Natural killer (NK) cells are a subset of lymphocytes that have innate immune functions, 67 
representing approximately 5–20 % of all lymphocytes in peripheral blood (Andoniou et al. 68 
2006).  NK cells are capable of recognizing and destroying certain tumour cells and virally-69 
infected cells without prior sensitization or specific antigen recognition, and therefore are 70 
distinct from other lymphocytes.  At rest (unstimulated) NK cells tend to express small 71 
amounts of functionally active CD69 (Borrego et al. 1999), however following activation this 72 
antigen is rapidly induced (Ziegler 1994). Although the exact role of CD69 has not as yet 73 
been elucidated, in vitro studies have demonstrated that once expressed on lymphocytes, this 74 
antigen appears to act as a co-stimulatory receptor helping to trigger subsequent cell 75 
proliferation, cytotoxicity and secretion of cytokines (such as tumour necrosis factor-α and 76 
interferon-γ) (Borrego et al. 1999).  However, in vivo studies have demonstrated that the 77 
behaviour of CD69 is more complex, and also appears to act as an immunoregulatory 78 
molecule (reviewed in Sancho et al. 2005).  Several studies have demonstrated that CD69 79 
cross-linking appears to induce the production of the anti-inflammatory cytokine transforming 80 
 
 
4 
growth factor-β (TGF- β) in lymphocytes, that appears to be able to downregulate the 81 
inflammatory response as well as tumour lysis by NK cells (Esplugues et al. 2003; Sancho et 82 
al. 2003).  83 
 84 
Acute strenuous exercise causes a temporary perturbation in a range of immune cell functions 85 
usually lasting between ~3-24 h.  It is suggested that during this “open window” of altered 86 
immunity, viruses and bacteria may gain a foothold, increasing the risk of subsequent 87 
infection (Nieman 2000).  Several studies have demonstrated that for several hours following 88 
both high intensity continuous and intermittent exercise NK cell number and function are 89 
suppressed to below baseline measures (Kappel et al. 1991; McFarlin et al. 2004; Neiman et 90 
al. 2007).  NK cells express both adenosine receptors (A1, A2A and A2B) and β2-91 
adrenoreceptors (Priebe et al. 1990; Shephard 2003). Caffeine is a non-selective adenosine 92 
receptor antagonist and also stimulates epinephrine release from the adrenal medulla; as such 93 
caffeine has the potential to either increase (via A2A receptor antagonism) or decrease (via A1 94 
receptor antagonism and/or increased epinephrine stimulation) NK cell activation depending 95 
upon the principal mechanism. Strenuous exercise increases the plasma concentrations of both 96 
adenosine and epinephrine (Nieman et al. 2007; Vizi et al. 2002) and it has been proposed that 97 
these increases predominately inhibit NK cell function in vitro and in vivo (Kappel et al. 98 
1991; Priebe et al. 1990), via A2A adenosine receptor and β2-adrenoreceptor activation of 99 
adenylate cyclase and increased intracellular cAMP  (Raskovalova et al. 2006). It is likely that 100 
in response to caffeine ingestion and exercise both adenosine and epinephrine mechanisms 101 
will be involved.  However, the overall affect on NK cell activation may depend upon which 102 
mechanism predominates. 103 
 104 
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Caffeine has been shown to increase sympathoadrenal medullary system (SAM) activity and 105 
as such plasma epinephrine concentration (reviewed in Graham 2001).  Salivary α-amylase 106 
activity is stimulated by increased activity of the sympathetic nervous system (Rohleder et al. 107 
2004).  Therefore, it has been suggested that elevations in α-amylase concentration can be 108 
considered a good indicator of enhanced sympathetic activity (Anderson et al. 1984; Rohleder 109 
et al. 2004).  As such salivary α-amylase has been chosen as a surrogate marker for plasma 110 
epinephrine concentration in the present study.  111 
   112 
Despite the reported widespread and frequent use of caffeine within society (Heatherley et al. 113 
2006), very few studies have investigated the effect of caffeine on immune cell responses to 114 
exercise in healthy individuals.  Of the handful of studies that have been published, all have 115 
administered 6 mg·kg-1 body mass caffeine in one bolus dose following a 60 h abstinence 116 
period (Bishop et al. 2005, 2006; Fletcher and Bishop 2010; Walker et al. 2006, 2007, 2008). 117 
However, caffeine is typically consumed in separate doses throughout the day, following an 118 
overnight abstention (Fredholm et al. 1999).  To the authors knowledge no study to date has 119 
attempted to model natural caffeine consumption in terms of dose and time of consumption 120 
when investigating caffeine’s effects on immune cell function following exercise.  Recent 121 
pilot work from our group has suggested that a small dose of caffeine (2 mg·kg-1) ingested 122 
prior to exercise increases antigen-stimulated NK cell CD69 expression 1 h following high 123 
intensity cycling to the same extent as that of a dose 3 times as large (6 mg·kg-1).  Therefore 124 
the aim of this study was to investigate whether small repeated doses (2 mg·kg-1) of caffeine 125 
ingested throughout the day (9:00 h, 12:00 h & 15:00 h) would elicit a similar response as one 126 
large (6 mg·kg-1) bolus dose ingested 1 h prior to exercise (15:00 h) compared with placebo 127 
on antigen-stimulated NK cell CD69 expression following 90 min of high intensity 128 
intermittent exercise.  It was hypothesised that both caffeine trials would increase NK cell 129 
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CD69 expression to a similar extent following high intensity intermittent exercise, and that 130 
this increase would be significantly greater when compared with placebo. 131 
 132 
Methods 133 
Participants 134 
Fifteen healthy male games (football and rugby) players [mean (SD): age 22 (2) years; body 135 
mass 76 (8) kg; max2OV  54 (3) ml·kg-1·min-1] volunteered to participate in this study.  All 136 
participants were fully informed about the rationale for the study and the design of the 137 
exercise tests and trial protocol, along with their possible risks and discomforts, before 138 
providing written informed consent.  The local Ethical Advisory Committee approved the 139 
study.  Participants did not report taking any medications or experiencing any symptoms of 140 
upper respiratory tract infection in the 4 weeks prior to the study.  All participants were 141 
moderate caffeine users (50 – 250 mg·day-1), with an average daily caffeine intake of 159 (61) 142 
mg·day-1. 143 
 144 
Preliminary testing 145 
Approximately 2 weeks before the beginning of the main trials, each participant was required 146 
to perform a progressive shuttle run test to volitional fatigue to estimate maximal oxygen 147 
consumption ( max2OV ) (Ramsbottom et al., 1988). From this estimate, running speeds 148 
corresponding to 55% and 95% max2OV  were calculated from the tables for predicted max2OV  149 
values (Ramsbottom et al., 1988).  Participants came back into the lab on a separate occasion 150 
to undertake a familiarization trial, which required them to perform 3x15 min blocks (45 min) 151 
of the LIST.  Heart rates (Polar FS1, Polar Electro Oy, Kempele, Finland) were monitored 152 
continuously during the familiarization trial.  153 
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 154 
Experimental trial procedures 155 
Participants were instructed to avoid alcohol consumption and strenuous physical activity in 156 
the 24 h preceding each experimental trial.  Participants were also instructed to stop 157 
consuming caffeine from 21:00 h the night before each trial.  In an attempt to standardize 158 
nutritional status, participants completed a 24 h food diary the day before and the day of the 159 
first main trial.  Participants were then asked to follow their food diaries for the second and 160 
third main trials.  Participants performed 3 main exercise trials, each separated by 1 week.  161 
Participants were randomly assigned to either the PLA, 1xCAF (1 single dose of 6 mg·kg-1 162 
caffeine) or 3xCAF (3 repeated doses of 2 mg·kg-1 caffeine) trial and acted as their own 163 
controls in a repeated-measures, single-blind, cross-over design.  Participants arrived at the 164 
laboratory at 08:50 h following an overnight fast of 12 h.  After 10 min of resting quietly an 165 
initial (pre-supplement) blood sample was obtained from an antecubital forearm vein by 166 
venepuncture.  Following the blood sample, an initial (09:00 h, pre-supplement) saliva sample 167 
was obtained.  Participants then ingested 0 (PLA) or 2 (3xCAF) mg·kg-1 body mass of 168 
caffeine powder (BDH Laboratory Supplies, Poole, UK) taken in the form of cellulose 169 
capsules (G & G Food Supplies Ltd, West Sussex, UK) with 300 ml plain water.  For the 0 170 
mg·kg-1 dose, participants ingested 2 mg·kg-1 body mass of dextrose powder (BDH 171 
Laboratory Supplies, Poole, UK).  The specific timings of PLA or CAF ingestion along with 172 
blood and saliva samples are illustrated in Fig. 1.  Participants then rested quietly in the 173 
laboratory for 1 h before a further (10:00 h) saliva sample was taken, after which participants 174 
were free to leave the laboratory and to start eating.  Participants were required to return to the 175 
laboratory at 12:00 h to ingest another set of either 0 (PLA) or 2 (3xCAF) mg·kg-1 caffeine 176 
capsules and to provide a further saliva sample (12:00 h).  After the saliva sample participants 177 
left the laboratory until 15:00 h, at which time they provided another saliva sample (15:00 h).  178 
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Participants stopped eating from 15:00 h. Participants then ingested a final set of either 0 179 
(PLA), 2 (3xCAF) or 6 (1xCAF) mg·kg-1 caffeine capsules immediately after the saliva 180 
sample. Participants then rested quietly in the laboratory for 1 h before a further venous blood 181 
and saliva sample (16:00 h, pre-exercise) were taken.  Immediately following venous blood 182 
and saliva samples pre-exercise body mass (in shorts only) was recorded, after which, 183 
participants began six 15 min periods of intermittent shuttle running, which consisted of ~10 184 
cycles of walking, maximal sprinting, jogging and cruising (Fig. 2).  Participants were 185 
required to run between two lines separated by 20 m at various speeds that related to previous 186 
max2OV  values. Each 15 min bout of running was separated by a 3 min rest period.  During 187 
this period participants were allowed to consume plain water ad libitum and were asked to 188 
rate their perceived exertion (RPE) on a Borg 6-20 scale. Heart rates were recorded prior to, 189 
during and immediately after each 15 min period of intermittent shuttle running.  A further 190 
venous blood and saliva sample (17:45 h, post-exercise) was obtained immediately after 191 
cessation of exercise, before post-exercise body mass (in shorts only) was recorded.  192 
Participants then consumed 5 ml·kg-1 body mass of plain water and rested quietly in the 193 
laboratory for a further hour before a final venous blood and saliva sample (18:45 h, 1 h post-194 
exercise) was obtained.  During this time no additional food or fluid was administered to 195 
participants.  For all venous blood samples, 20 ml of blood was obtained, with all samples 196 
taken from participants in an upright-seated position.  For all saliva samples, participants were 197 
asked to swallow to empty the mouth before timed unstimulated whole mixed saliva 198 
collections were made into pre-weighed sterile vials (7 ml capacity bijou tubes with screw-199 
top). All collections were made over a 2 min period, unless insufficient volume had been 200 
produced, in which case the collection period was increased to 3 min, as necessary.  All 201 
collections were made with participants seated; leaning forwards and with their heads tilted 202 
downwards.  Participants were instructed to allow the saliva to dribble into the tube with 203 
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minimal orofacial movement.  Laboratory conditions throughout the study were 20.5 (0.9) °C 204 
and 35.7 (5.4) % relative humidity.   205 
 206 
Total lymphocyte count and plasma volume 207 
Blood samples were collected into two evacuated monovette tubes (Starstedt, Leicester, UK), 208 
one containing K3EDTA (1.6 mg EDTA ml-1 blood) and one containing no additive to obtain 209 
serum, as well as a sterile 5 ml bijou tube (Sterilin, Staffordshire, UK) containing 15 µl 210 
sodium heparin (15 IU heparin ml-1 blood).  Blood collected into the K3EDTA monovette (7.5 211 
ml) was analyzed for total and differential leukocyte counts, hematocrit and hemoglobin 212 
contents using a hematology analyzer (AC.TTM 5diff analyzer, Beckman Coulter, UK).  213 
Plasma volume changes were estimated according to Dill and Costill (1974). 214 
 215 
Lymphocyte culture 216 
Five ml of whole blood transferred into the sterile bijou tube containing heparin was 217 
immediately placed on ice and mixed (Thermo Denley, Spiramix) for 20 min before setting 218 
up cultures. Due to the large time gap (6 h) between pre-supplement and pre-exercise venous 219 
blood samples, 2 lots of cultures were set up: one set was the pre-supplement sample, the 220 
other set was the pre-exercise, post-exercise and 1 h post-exercise samples.  Cells were 221 
cultured in Falcon 12 x 75 mm-polystyrene tubes with caps (Becton Dickinson Biosciences, 222 
Oxford, UK) and for all samples stimulated and unstimulated cultures were set up.  Tubes 223 
were stimulated by a 1:400 or 1:800 Pediacel vaccine (Sanofi Pasteur MSD Ltd, Berkshire, 224 
UK), containing diphtheria toxoid, tetanus toxoid, acellular pertussis bacteria, poliovirus and 225 
haemophilus influenza type b.  Zero or 20 µl of Pediacel working vaccine (either 1:400 or 226 
1:800) was added to 200 µl of heparinized whole blood, giving a final stimulant concentration 227 
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of 1:4000 (optimum) or 1:8000 (sub-optimum) before being incubated for 20 h at 37 °C, 5% 228 
CO2. All cell culture work was carried out in a class II laminar flow hood (Esco GB Ltd, 229 
Salisbury, UK) by using aspectic techniques. 230 
 231 
Assessment of lymphocyte subsets and CD69 expression 232 
After incubation, peripheral blood cells were labelled with a cocktail of Pharmingen 233 
monoclonal antibodies (Becton Dickinson Biosciences, Oxford, UK) against human 234 
lymphocyte cell surface markers, as follows: 5 µl CD3 FITC, 20 µl CD56 PECy5 and 10 µl 235 
CD69 PE.  All samples were then vortexed and placed on ice for 20 min, after which 236 
erythrocytes were lysed and leukocytes fixed using FACS Lyse (Becton Dickinson, Oxford, 237 
UK).  Leukocytes were washed once in 3 ml ice cold phosphate-buffered saline (PBS) 238 
containing 0.1% bovine serum albumin (BSA) and 2 mM EDTA (PBS/BSA/EDTA) before 239 
being resuspended in 400 µl PBS/BSA/EDTA.  Three-colour flow cytometric analysis was 240 
performed using a FACS Calibur flow cytometer with Cell Quest analysis software (Becton 241 
Dickinson, Oxford, UK).  Standard gating procedures using side scatter versus forward scatter 242 
plots were used to gate on the lymphocyte population.  An unstained unstimulated sample was 243 
used to set quadrant boundaries to allow accurate acquisition of stained samples. All samples 244 
were set to collect 30,000 lymphocyte events per analysis.   245 
 246 
CD3+ (T cell region) and CD56+ (NK cell region) populations were acquired on quadrant dot 247 
plots of FL1 (CD3 FITC) and FL3 (CD56 PE-Cy5), along with quadrant dot plots of FL1 248 
(CD3) and FL2 (CD69 PE) and quadrant dot plots of FL3 (CD56) and FL2 (CD69).  This data 249 
was then displayed as histogram plots and the percentage of CD3- cells (total lymphocyte 250 
region minus the CD3+ region) expressing CD56+ were derived and from this the percentage 251 
of total lymphocytes that were CD3-CD56+ was determined.  CD3-CD56+ cells were then 252 
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gated into a separate region and a CD69+ histogram plot of the cells within this region was 253 
used to calculate the percentage expression and geometric mean fluorescence intensity 254 
(GMFI) expression of CD69 of CD3-CD56+ cells. Cell counts of CD3-CD56+ were calculated 255 
by multiplying the percentage of these cells with the absolute lymphocyte count.  The number 256 
of CD3-CD56+ cells expressing CD69 were determined by multiplying the percentage of cells 257 
expressing CD69 by the total number of CD3-CD56+ cells.  To facilitate intersubject 258 
comparisons, pre-exercise, post-exercise and 1 h post-exercise CD69 GMFI were expressed 259 
as a percentage of the pre-supplement value, as according to Timmons et al. (2006). 260 
 261 
Saliva flow rate 262 
Saliva samples were stored in their plastic containers at –80 °C prior to analysis. Saliva 263 
volume was estimated by weighing the bijou tubes to the nearest mg before and after saliva 264 
collection. Saliva density was assumed to be 1.00 g.ml-1 (Cole and Eastoe 1988) and from 265 
this, the saliva flow rate (μl·min-1) was determined by dividing the volume of saliva by the 266 
collection time.  267 
 268 
Saliva α-amylase 269 
Saliva α-amylase activity was measured using a commercially available kit (InfinityTM 270 
Amylase Liquid Stable Reagent, Thermo Scientific, UK), with proportional reduction of 271 
volumes so that the assay could be carried out in a microtitration (96-well) plate.  Briefly, 20 272 
μl saliva diluted 1:100 with 1.0 mM CaCl2 was mixed with 180 μl of amylase reagent.  The 273 
plate was incubated for 1 min at 25°C and then the increase in absorbance at 405 nm was 274 
recorded every min for a further 4 min period on an automated plate reader.  Purified α-275 
amylase from human saliva (A1031, Sigma) was used as a standard.  The secretion rate of α-276 
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amylase (U·min-1) was calculated by multiplying the saliva flow rate by the α-amylase 277 
activity.  The intra assay coefficient of variation for α-amylase was 1.1% 278 
 279 
Serum and saliva caffeine concentration 280 
Serum was obtained from whole blood collected into a serum monovette (5.5 ml), which was 281 
left to clot for 1 h before being centrifuged at 1500 g for 10 min in a refrigerated centrifuge at 282 
4 ºC.  Saliva samples were transferred into eppendorfs and centrifuged at 12000 rpm for 2 min 283 
in a high speed microcentrifuge. Serum and saliva caffeine concentration was determined 284 
using a commercially available kit (Emit Caffeine Assay, Dade-Behring, Milton Keynes, UK) 285 
on an automatic photometric analyzer (COBAS Miras Plus, Roche Diagnostic Systems, 286 
Switzerland).  The intra assay coefficient of variation for serum and saliva caffeine 287 
concentration was 2.6% and 1.7%, respectively.   288 
 289 
Statistical analysis 290 
Data in the text, tables and figures are presented as mean values and their standard deviation 291 
(± SD).  The data were examined using a two-factor (trial x time) analysis of variance 292 
(ANOVA) with repeated measures design.  If the data were not normally distributed, 293 
statistical analysis was carried out on the logarithmic transformation of the data.  Assumptions 294 
of sphericity in the data were checked, and adjustments in the degrees of freedom for the 295 
ANOVA were made using the Huynh-Feldt method of correction where appropriate.  Any 296 
significant data were assessed using Student’s paired t-tests with Holm-Bonferroni 297 
adjustments for multiple comparisons.  Statistical significance for this study was accepted at 298 
P<0.05.  The observed powers of the reported main and interaction effects are all >0.8. 299 
 300 
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Results 301 
Physiological measurements 302 
There were no differences in ratings of perceived exertion between trials during the test [RPE 303 
of 13 (2) for all trials].  Likewise, heart rates were similar between trials during exercise 304 
[PLA: 171 (12) beat·min-1, 1xCAF: 175 (13) beat·min-1, 3xCAF: 177 (12) beat·min-1; mean 305 
of all recordings]. 306 
 307 
Changes in body mass and plasma volume 308 
After exercise, changes in body mass (corrected for fluid intake) were similar for all trials 309 
[PLA: -1.8 (0.3) kg, 1xCAF: -1.8 (0.3) kg, 3xCAF: -1.9 (0.4) kg].  There was no significant 310 
time x trial interaction effect for changes in plasma volume relative to the initial blood 311 
sample.  After exercise plasma volume decreased by 3.3 (4.4) %, 3.4 (6.0) % and 4.8 (6.6) % 312 
on the PLA, 1xCAF and 3xCAF trials, respectively. 313 
 314 
Serum caffeine concentration 315 
A significant time x trial interaction was found for serum caffeine concentration (P<0.01), 316 
with higher concentrations at pre (16:00 h), post (17:45 h) and 1 h post-exercise (18:45 h) on 317 
both 1xCAF and 3xCAF compared with PLA (P<0.01; Fig. 3).  Serum caffeine concentration 318 
was also significantly higher on 3xCAF at pre-exercise compared with 1xCAF (P<0.05).  319 
However at post-exercise and 1 h post-exercise serum caffeine concentrations on 1xCAF were 320 
significantly higher than 3xCAF (both P<0.01; Fig 3). 321 
 322 
Saliva caffeine concentration 323 
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A significant time x trial interaction was found for saliva caffeine concentration (P<0.01), 324 
with higher concentrations at 10:00 h, 12:00 h, 15:00 h and pre (16:00 h), post (17:45 h) and 1 325 
h post-exercise (18:45 h) on 3xCAF compared with PLA (P<0.01; Table 1) and at post (17:45 326 
h) and 1 h post-exercise (18:45 h) on 1xCAF compared with PLA (P<0.01; Table 1).  Saliva 327 
caffeine concentrations were also higher on 3xCAF at 10:00 h, 12:00 h, 15:00 h and pre-328 
exercise compared with 1xCAF (P<0.01; Table 1), but lower than 1xCAF at post and 1 h 329 
post-exercise (P<0.01; Table 1). 330 
 331 
Saliva flow rate 332 
Saliva flow rate appeared to increase significantly above pre-supplement (9:00 h) values at 333 
10:00 h, 12:00 h, 15:00 h, pre-exercise, post-exercise and 1 h post-exercise (main effect for 334 
time: all time points P<0.01, except post-exercise P<0.05; Table 1).  However, when 335 
compared against pre-exercise values, saliva flow rate fell significantly at post-exercise (main 336 
effect for time: P<0.01; Table 1).  There were no significant effects of trial/treatment. 337 
 338 
Saliva α-amylase 339 
A significant time x trial interaction was found for saliva α-amylase activity, which was 340 
significantly higher at pre-exercise and 1 h post-exercise on both 1xCAF and 3xCAF 341 
compared with PLA (P<0.05; Table 1).  A significant time x trial interaction was also found 342 
for saliva α-amylase secretion rate, which was higher at 1 h post-exercise on 1xCAF 343 
compared with PLA (P<0.05; Table 1).  There were no differences between 1xCAF and 344 
3xCAF. 345 
 346 
Circulating lymphocyte counts and numbers of CD3-CD56+ cells 347 
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There were no time x trial interactions for the number of circulating lymphocytes, but there 348 
was a main effect for time (P<0.01) with the number of circulating lymphocytes increasing 349 
above pre-supplement values at immediately post-exercise (P<0.01; Table 2).  A significant 350 
time x trial interaction was found for the number of CD3-CD56+ cells within the circulating 351 
lymphocyte population (P<0.01), with a higher number of CD3-CD56+ cells found at post-352 
exercise on both 1xCAF and 3xCAF compared with PLA (P<0.05; Table 2).  There were no 353 
differences between 1xCAF and 3xCAF. 354 
 355 
Number of unstimulated and antigen-stimulated CD3-CD56+ cells expressing CD69 356 
There were no interaction effects for the number of unstimulated CD3-CD56+ cells expressing 357 
CD69.  However there was a main effect for time (P<0.01) with the number of CD3-CD56+ 358 
cells expressing CD69 increasing significantly above pre-supplement values at pre and post-359 
exercise, only to fall below pre-supplement values at 1 h post-exercise (all P<0.01; Fig. 4a).  360 
When cells were stimulated there was a significant time x trial interaction effect, with the 361 
number of antigen-stimulated (both doses) CD3-CD56+ cells expressing CD69 lower at 1 h 362 
post-exercise on 1xCAF compared with PLA (P<0.05); values on 1xCAF at this time-point 363 
remained close to pre-supplement (Fig. 4b & c).  There were no differences between 3xCAF 364 
and PLA or 1xCAF and 3xCAF. 365 
 366 
Geometric Mean Fluorescence Intensity of CD69 expression on unstimulated and antigen-367 
stimulated CD3-CD56+ cells 368 
There were no significant interaction effects for the GMFI of CD69 expression on 369 
unstimulated CD3-CD56+ cells.  However there was a main effect for time (P<0.01), with the 370 
GMFI of CD69 expression on unstimulated CD3-CD56+ cells increasing significantly above 371 
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pre-supplement values at 1 h post-exercise (P<0.01; Fig. 5a).  When cells were stimulated 372 
there was a significant time x trial interaction effect, with the GMFI of CD69 expression on 373 
antigen-stimulated (1:8000) CD3-CD56+ cells increasing on all trials above pre-supplement 374 
values at 1 h post-exercise (P<0.01; Fig. 5c).    However, values tended to be lower on 1xCAF 375 
compared with PLA at this time (P=0.055; Fig. 5c).  The GMFI of CD69 expression on 376 
antigen-stimulated (1:8000) CD3-CD56+ cells was also significantly lower at immediately 377 
post-exercise on 1xCAF compared with both PLA and 3xCAF (P<0.05), with values on 378 
1xCAF at this time-point remaining close to pre-supplement values (Fig. 5c).   379 
 380 
Discussion 381 
The main findings of this study suggest that exercise induced an increase in the number of 382 
antigen-stimulated NK cells expressing CD69 as well as in the GMFI of CD69 expression on 383 
antigen-stimulated NK cells 1 h following 90 min shuttle running that was attenuated after 384 
consuming one large bolus dose (6 mg·kg-1) of caffeine 1 h before exercise (15:00 h; 1xCAF).  385 
In contrast, ingesting small doses (2 mg·kg-1) of caffeine throughout the day to model a more 386 
typical pattern of caffeine consumption (09:00 h, 12:00 h & 15:00h; 3xCAF) had little effect 387 
on antigen-stimulated NK cell CD69 expression.  388 
 389 
It has been suggested that caffeine’s main mechanism of action is predominately via A2A 390 
adenosine receptor antagonism (Fredholm et al. 1999).  As such it was speculated that in the 391 
present study both caffeine trials would have increased antigen-stimulated NK cell CD69 392 
expression in response to exercise compared with placebo as has previously been found 393 
(Fletcher and Bishop 2010).  However, this was not the case in this study and as such appears 394 
to indicate that in the present study A2A adenosine receptor antagonism was not the 395 
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predominant mechanism involved.  NK cells also possess A1 adenosine receptors (Priebe et 396 
al. 1990).  As a non-selective adenosine receptor antagonist, caffeine could have antagonized 397 
NK cell A1 receptors (Fredholm et al. 1999), which may have restricted the increase in 398 
antigen-stimulated NK cell CD69 expression on both caffeine trials in response to high 399 
intensity intermittent exercise compared with placebo.   400 
 401 
It could be suggested that the large bolus dose of caffeine attenuated the exercise-induced 402 
increase in NK cell CD69 expression following high intensity shuttle running via stimulating 403 
the release of epinephrine.  Epinephrine stimulates β2-adrenoreceptors found on NK cells, 404 
leading to an increase in intracellular cAMP levels.  An increase in the concentration of 405 
cAMP in the cell may have interfered with signals that are necessary for adhesion 406 
strengthening (Benschop et al. 1997) and as such could have preferentially mobilized a less 407 
active subset of NK cells into the circulation following exercise.  Epinephrine has also been 408 
shown to inhibit CD69 expression on mitogen-stimulated NK cells (Shimamiya et al. 2003) 409 
and as such may have been responsible for the lower number of antigen-stimulated NK cells 410 
expressing CD69 and GMFI expression of CD69 on antigen-stimulated NK cells following 411 
the large single dose caffeine trial compared with placebo 1 h following high intensity shuttle 412 
running. 413 
 414 
Although plasma epinephrine concentrations were not directly determined in this study, saliva 415 
α-amylase activity and secretion rate were measured as a surrogate marker, as increases in α-416 
amylase concentration are considered a good indicator of enhanced sympathetic activity 417 
(Anderson et al. 1984; Rohleder et al. 2004).  Saliva α-amylase activity was significantly 418 
higher at 1 h post-exercise on both caffeine trials compared with placebo.  However, only the 419 
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large single dose caffeine trial (1xCAF) showed a significantly higher α-amylase secretion 420 
rate at 1 h post-exercise compared with placebo.  As such this may explain why in the present 421 
study this was the only caffeine trial to attenuate the exercise-induced increase in both the 422 
number of antigen-stimulated NK cells expressing CD69 and their intensity of CD69 423 
expression following high intensity shuttle running.  Large (6 and 9 mg·kg-1), but not small (3 424 
mg·kg-1), doses of caffeine have been shown to increase plasma epinephrine concentration in 425 
response to high intensity exercise (Graham and Spriet 1995; Walker et al. 2006).  Therefore, 426 
it could perhaps be suggested that there may be an epinephrine threshold, above which 427 
epinephrine produces inhibitory effects upon NK cell CD69 expression.  However, as plasma 428 
epinephrine concentrations were not directly determined in this study, any explanation as to 429 
how the large bolus dose of caffeine attenuated the exercise-induced increase in antigen-430 
stimulated NK cell CD69 expression following exercise is only speculation and as such is a 431 
limitation of this study. 432 
 433 
The increase in number of antigen-stimulated NK cells expressing CD69 following exercise 434 
on PLA could be interpreted in a number of ways due to the multiple complex actions of 435 
CD69.  One could suggest that this increase may augment subsequent proliferation, 436 
cytotoxicity and pro-inflammatory cytokine release that would appear to favour a pro-437 
inflammatory response via the actions of CD69 as a co-stimulatory receptor (Borrego et al. 438 
1999).   However, CD69 has also been shown to act as a negative regulator, downregulating 439 
the ability of NK cells to lyse target cells due to the production of TGF-β (Esplugues et al. 440 
2003).  As such the increase in the number of NK cells expressing CD69 in response to 441 
antigen may act as a regulatory response.  However, given that TGF- β release by CD69+ NK 442 
cells was not determined it is difficult to ascertain the exact role of CD69 in this study.  443 
Future in vitro work to determine the nature of the response (e.g. assessment of TGF-β 444 
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release) would provide greater insight regarding to the physiological nature and implications 445 
of these findings. 446 
 447 
Alternatively, it could be argued that as participants were habitual caffeine users, the effects 448 
of caffeine on antigen-stimulated NK cell CD69 expression in response to prolonged high 449 
intensity exercise in this study may have resulted from participants’ tolerance to the effects of 450 
caffeine.  It has been demonstrated that tolerance to some of the effects of caffeine can 451 
develop quite quickly in habitual caffeine users (reviewed in Fredholm et al. 1999). Studies 452 
both in rats and humans suggest that following chronic caffeine intake (~14 days) A1 and A2A 453 
adenosine receptors are upregulated leading to an increased sensitivity to adenosine 454 
(Johansson et al. 1997; Varani et al. 2005). Therefore, as participants were only required to 455 
abstain from caffeine overnight, caffeine habituation may have contributed towards the 456 
findings that one large bolus dose of caffeine attenuated the exercise-induced increase in 457 
antigen-stimulated NK cell CD69 expression 1 h following high intensity shuttle running yet 458 
small repeated doses of caffeine had little effect at all.  It should be noted that the mechanisms 459 
discussed here are unlikely to occur exclusively; therefore these findings are likely to be the 460 
net result of several positive and negative influences. 461 
 462 
The issue of tolerance could also help explain why the findings of the present study contrast 463 
with our previous results when caffeine ingestion (2 and 6 mg·kg-1) increased antigen 464 
stimulated NK cell CD69 expression 1 h following 90 min high intensity exercise compared 465 
with placebo (Fletcher and Bishop in press). Tolerance to caffeine dissipates after its 466 
discontinuation, with resensitization to caffeine usually occurring within 2-3 days of 467 
abstention (Benowitz et al. 1995; Varani et al. 2005). Our previous work employed a 60 h 468 
caffeine abstention period and as such likely controlled for any influence of caffeine 469 
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tolerance. The mode of exercise in the present study was also different to that used in our 470 
previous work (intermittent running and continuous cycling, respectively) and may have 471 
influenced caffeine metabolism and as such caffeine’s effects. However, this seems unlikely 472 
as Graham and Spriet (1991) have reported no difference in caffeine metabolism or plasma 473 
epinephrine concentration between running and cycling to exhaustion. In addition, serum 474 
caffeine concentrations immediately following 90 min continuous cycling (Fletcher and 475 
Bishop 2010) and intermittent running (present study) with prior ingestion of 6 mg·kg-1 body 476 
mass caffeine showed comparable values (continuous cycling, 44 μM; intermittent running, 477 
43 μM). 478 
 479 
One limitation of this study was the absence of a resting trial to determine if caffeine acted on 480 
antigen-stimulated NK cell CD69 expression without the influence of exercise.  Initial pilot 481 
work from our group that looked at NK cell responses to caffeine at rest between 08:30 h and 482 
12:00 h suggests that caffeine at doses of 2 or 6 mg·kg-1 body mass ingested in one bolus dose 483 
at 08:30 h have little effect on antigen-stimulated NK cell CD69 expression up until 12:00 h.   484 
 485 
In conclusion, the findings of the present study suggest that exercise induced an increase in 486 
the number of antigen-stimulated NK cells expressing CD69 as well as their intensity of 487 
CD69 expression 1 h following 90 min shuttle running that was attenuated by one large bolus 488 
dose (6 mg·kg-1) of caffeine ingested 1 h prior to exercise.  In contrast, small doses (2 mg·kg-489 
1) of caffeine ingested throughout the day to model a more typical pattern of caffeine 490 
consumption had little effect on antigen-stimulated NK cell CD69 expression.  It should be 491 
noted that the attenuations seen with one large bolus dose of caffeine at no point fell below 492 
pre-supplement values and as such suggests that caffeine does not depress antigen-stimulated 493 
NK cell CD69 expression following 90 min of high intensity shuttle running.  494 
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Figure captions 595 
Fig. 1 Schematic representation of the trial protocol 596 
Fig. 2 Schematic representation of the Loughborough Intermittent Shuttle Running Test 597 
(LIST).  Adapted from Bishop et al. 2002 598 
Fig. 3 Serum caffeine concentrations during PLA, 3xCAF and 1xCAF trials.  * significantly 599 
higher than PLA (P<0.01). ** significantly higher than PLA and 3xCAF (P<0.01).                        600 
§ significantly higher than PLA and 1xCAF (P<0.01). † significantly higher than pre-601 
supplement within trial (P<0.01).    Values are means ± SD 602 
Fig. 4 Number of (a) unstimulated (b) 1:4000 antigen-stimulated, (c) 1:8000 antigen-603 
stimulated CD3-CD56+ NK cells expressing CD69 within the circulating lymphocyte 604 
population during PLA, 3xCAF and 1xCAF trials.  * significantly lower than PLA (P<0.05); 605 
† significantly higher than pre-supplement within trial (P<0.01). Values are means + SD 606 
Fig. 5 Geometric Mean Fluorescence Intensity of CD69 expression on (a) unstimulated (b) 607 
1:4000 antigen-stimulated, (c) 1:8000 antigen-stimulated CD3-CD56+ NK cells within the 608 
circulating lymphocyte population during PLA, 3xCAF and 1xCAF trials. * significantly 609 
lower than PLA and 3xCAF (P<0.05); † significantly higher than pre-supplement within trial 610 
(P<0.01). Values are means + SD and are expressed as a percentage of the pre-supplement 611 
value 612 
613 
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Table 1 Saliva caffeine concentration, flow rate, α-amylase activity and secretion rate during PLA, 3xCAF and 671 
1xCAF trials  672 
 673 
Values are means (SD) 674 
* P<0.01, ** P<0.05: significantly higher than PLA 675 
‡ significantly higher than 1xCAF, P<0.01 676 
§ significantly higher than 3xCAF, P<0.01 677 
† P<0.01: significantly higher than pre-supplement within trial 678 
a main effect for time; significantly higher than pre-supplement at all other time-points, all P<0.01 except for 679 
post-exercise P<0.05 680 
b main effect for time; significantly lower than pre-exercise at post-exercise, P<0.01 681 
682 
 09:00 h 
(Pre-
supplement) 
10:00 h 12:00 h 15:00 h 16:00 h 
(Pre-exercise) 
17:45 h 
(Post-
exercise) 
18:45 h 
(1 h post-
exercise) 
Saliva caffeine concentration (µmol·L-1) 
PLA 
3xCAF 
1xCAF 
1 (1) 
1 (1) 
1 (1) 
1 (1) 
10 (4)*‡ 
0 (0) 
1 (1) 
8 (2)*‡ 
0 (0) 
1 (1) 
14 (3)*‡ 
1 (1) 
0 (0) 
15 (3)*‡ 
2 (2) 
0 (0) 
20 (5)*‡ 
30 (4)*§ 
0 (0) 
19 (4)*‡ 
27 (4)*§ 
Saliva flow rate (µl·min-1) a,b 
PLA 
3xCAF 
1xCAF 
441 (268) 
431 (216) 
423 (241) 
549 (252) 
571 (254) 
575 (240) 
543 (180) 
586 (185) 
546 (203) 
567 (203) 
591 (294) 
566 (165) 
572 (200) 
585 (252) 
642 (223) 
484 (171) 
467 (209) 
520 (203) 
683 (248) 
656 (286) 
698 (225) 
Saliva α-amylase activity (U·ml-1) 
PLA 
3xCAF 
1xCAF 
392 (257) 
306 (271) 
368 (299) 
439 (243) 
608 (346) 
545 (290) 
793 (416) 
845 (319) 
905 (442) 
967 (373) 
936 (316) 
925 (345) 
827 (373)† 
997 (313)**† 
1023 (369)**† 
1456 (530)† 
1719 (527)† 
1615 (457)† 
867 (494)† 
1098 (430)**† 
1196 (402)**† 
Saliva α-amylase secretion rate (U·min-1) 
PLA 
3xCAF 
1xCAF 
174 (167) 
138 (151) 
157 (154) 
234 (150) 
239 (291) 
314 (192) 
444 (284) 
526 (353) 
497 (293) 
569 (433) 
570 (357) 
494 (188) 
487 (323)† 
587 (357)† 
660 (327)† 
695 (343)† 
810 (470)† 
812 (338)† 
580 (391)† 
742 (452)† 
804 (289)**† 
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Table 2 Number of circulating lymphocytes and CD3-CD56+ cells within the circulating lymphocyte  683 
population during PLA, 3xCAF and 1xCAF trials  684 
 685 
 686 
 687 
 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
Values are means (SD) 704 
* P<0.01; ** P<0.05, significantly higher than PLA 705 
† P<0.01; †† P<0.05, significantly higher than pre-supplement within trial 706 
a main effect for time; significantly higher than pre-supplement at post-exercise, P<0.01 707 
 708 
 709 
 710 
 711 
 Pre-supplement Pre-exercise  Post-exercise  1 h post-exercise 
Lymphocytes (x109 cells.L-1) a 
PLA 
3xCAF 
1xCAF 
2.10 (0.50) 
2.10 (0.70) 
2.10 (0.40) 
2.10 (0.50) 
2.00 (0.50) 
2.10 (0.40) 
2.90 (0.80) 
3.10 (1.00) 
3.20 (0.80) 
2.10 (0.50) 
1.90 (0.50) 
1.90 (0.60) 
CD3-CD56+ cells (x109 cells.L-1) 
PLA 
3xCAF 
1xCAF 
0.26 (0.08) 
0.28 (0.09) 
0.29 (0.11) 
0.30 (0.09) 
0.35 (0.10)†† 
0.36 (0.09)†† 
0.53 (0.16)† 
0.70 (0.22)**† 
0.80 (0.32)*† 
0.25 (0.07) 
0.25 (0.07) 
0.27 (0.09) 
